Below is the text of the article that pertains to LIFE:
"Investors in StemCells are somewhat justified in their exuberance over the ruling. In addition to developing stem cell therapies for spinal cord injuries and other disorders, StemCells sells reagents that help scientists grow stem cells. Like Life Technologies (Nasdaq: LIFE ) , which sells similar products, StemCells reagent sales would be severely hurt if the ban had gone through. Long term, the value of StemCells should be tied to its clinical therapies, but in the short term, revenue from reagents sales is helpful.
This isn't the end of the fight over federal funding. There will likely be appeals to the full appeals court and all the way to the Supreme Court, but hopefully this is the end of overreactions by investors."
Wishing you and all LIFE shareholders prosperity & the best "LIFE" has to offer.